ArticleDiagnostic and interventional radiology (Ankara, Turkey)2026
T2 signal ratio enhances the diagnostic performance of apparent diffusion coefficient in differentiating orbital lymphoma from inflammatory mimickers.
Article in Diagnostic and interventional radiology (Ankara, Turkey), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOrbital lymphomas share overlapping clinical and radiological features with immunoglobulin G4-related orbital disease (IgG4-ROD) and granulomatous orbital diseases, which may lead to diagnostic delays. This study aims to evaluate the added diagnostic value of the transverse relaxation time (T2) signal ratio when combined with apparent diffusion coefficient (ADC) measurements in distinguishing orbital lymphoma from inflammatory mimickers.
methodsIn this retrospective study, two blinded radiologists independently measured T2 signal ratios (lesion to cerebral cortex), ADC values, and ADC ratios on pretreatment orbital magnetic resonance imaging scans of 58 patients (21 lymphomas, 21 IgG4-ROD, 16 granulomatous inflammation). Measurements were performed on axial images at the lesion's maximal diameter. Regions of interest were manually drawn to cover the entire lesion, avoiding necrosis and edges. Diagnostic performance was assessed using receiver operating characteristic curve analysis, with optimal cut-off values determined by Youden's index. The ADC ratio (≤1) and T2 signal ratio (>0.88) were combined using OR (either positive) and AND (both positive) rules. Interobserver agreement was evaluated using intraclass correlation coefficients (ICC).
resultsAll measurements showed statistically significant differences between the two cohorts. Reviewer 1's ADC ratio measurements demonstrated excellent diagnostic performance, with an area under the curve (AUC) of 0.920 (85.7% sensitivity and 86.5% specificity at the optimal cut-off of ≤1). In comparison, T2 signal ratios showed moderate diagnostic value (AUC: 0.726; 80.95% sensitivity and 64.86% specificity at a cut-off >0.88). The combination of both parameters significantly improved diagnostic accuracy: the OR rule (ADC ≤1 or T2 >0.88) increased sensitivity to 95.2%, whereas the AND rule (ADC ≤1 and T2 >0.88) increased specificity to 94.6%. Interobserver reliability was excellent, with ICC values ranging from 0.969 to 0.985.
conclusionAlthough diffusion imaging remains the primary discriminator for orbital lymphoma, the T2 signal ratio considerably enhances diagnostic confidence, particularly in borderline ADC cases. CLINICAL SIGNIFICANCE: Incorporating T2 signal ratio measurements adds minimal workflow burden in routine clinical practice and provides a practical tool for differentiating lymphoma from IgG4-ROD and granulomatous inflammatory mimics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.